Bioactive Hexapeptide Reduced the Resistance of Ovarian Cancer Cells to DDP by Affecting HSF1/HSP70 Signaling Pathway

Overview

Journal J Cancer

Specialty Oncology

Date 2021 Sep 20

PMID 34539881

Citations 2

Authors

Ruowen Guo

Qia Xu

Liwei Liu

Hui Liu

Yun Liu

Wenmei Wei

Yide Qin

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer is the leading cause of death in gynecologic malignancies. Ovarian cancer as a metastatic malignant tumor is highly recurrent and prone to drug resistance. Bioactive peptides are an emerging area of biomedical research in reducing resistance of tumor cell to drugs. In this paper, we investigated the effects and mechanisms of bioactive hexapeptide (PGPIPN) derived in milk protein on the sensitivity of ovarian cancer cells to cis-dichlorodiammine platinum (DDP). Human ovarian cancer cell lines (SKOV3 and COC1), their DDP-resistant sublines (SKOV3/DDP and COC1/DDP) and human primary ovarian cancer cells were cultured under the combined treatment of DDP (close to IC50) and different concentrations of PGPIPN. The viabilities, apoptosis and cell cycle changes were respectively measured by WST-8 and flow cytometry. The mRNA and protein expression levels of HSF1, HSP70, MDR1, ERCC1 and β-actin gene were respectively assayed by RT-qPCR and western blotting. The results showed that PGPIPN significantly increased the sensitivity of human ovarian cancer cells to DDP in inhibiting viability and inducing apoptosis . But the effects in sensitive cells were lower than DDP-resistant cells. PGPIPN significantly changed the cell cycles in all human ovarian cancer cells, which leaded to a significant increase in the percentage of cells blocked at G2/M phase and decrease the percentage of cells at G1 phases in a dose-dependent manner. PGPIPN affected the expression levels of HSF1, HSP70, MDR1 and ERCC1 genes. Compared with cells in DDP treatment alone, the expression levels of HSF1 and HSP70 in human ovarian cancer cells treated with DDP and PGPIPN together significantly decreased in dose-dependent manner. PGPIPN significantly decreased MDR1 and ERCC1 of drug-resistant ovarian cancer cell lines and human primary ovarian cancer cell in a dose-dependent manner. Pifithrin-μ (PFTμ, HSP70 inhibitor) decreased or removed the effects of peptide in increasing the sensitivity of ovarian cancer cells to DDP. This suggests that PGPIPN enhanced the sensitivity of ovarian cancer cells to DDP partially via reducing the activity of HSF1/HSP70 signaling pathway, thus inducing cell apoptosis and decreasing repairment of DNA damage.

Citing Articles

Bioactive milk peptides: an updated comprehensive overview and database.

Nielsen S, Liang N, Rathish H, Kim B, Lueangsakulthai J, Koh J Crit Rev Food Sci Nutr. 2023; 64(31):11510-11529.

PMID: 37504497 PMC: 10822030. DOI: 10.1080/10408398.2023.2240396.

Targeting HSF1 for cancer treatment: mechanisms and inhibitor development.

Chin Y, Gumilar K, Li X, Tjokroprawiro B, Lu C, Lu J Theranostics. 2023; 13(7):2281-2300.

PMID: 37153737 PMC: 10157728. DOI: 10.7150/thno.82431.

References

Chen L, Yang X . TRIM11 cooperates with HSF1 to suppress the anti-tumor effect of proteotoxic stress drugs. Cell Cycle. 2018; 18(1):60-68. PMC: 6343683. DOI: 10.1080/15384101.2018.1558870. View

Aaghaz S, Gohel V, Kamal A . Peptides as Potential Anticancer Agents. Curr Top Med Chem. 2019; 19(17):1491-1511. DOI: 10.2174/1568026619666190125161517. View

Fekete J, osz A, Pete I, Nagy G, Vereczkey I, Gyorffy B . Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients. Gynecol Oncol. 2020; 156(3):654-661. DOI: 10.1016/j.ygyno.2020.01.006. View

Izaguirre D, Ng C, Kwan S, Kun E, Tsang Y, Gershenson D . The Role of GDF15 in Regulating the Canonical Pathways of the Tumor Microenvironment in Wild-Type p53 Ovarian Tumor and Its Response to Chemotherapy. Cancers (Basel). 2020; 12(10). PMC: 7650722. DOI: 10.3390/cancers12103043. View

Wang Z, Li F, Wei M, Zhang S, Wang T . Circadian Clock Protein PERIOD2 Suppresses the PI3K/Akt Pathway and Promotes Cisplatin Sensitivity in Ovarian Cancer. Cancer Manag Res. 2020; 12:11897-11908. PMC: 7683831. DOI: 10.2147/CMAR.S278903. View

Li X, Wu H, Ouyang X, Zhang B, Su X . New bioactive peptide reduces the toxicity of chemotherapy drugs and increases drug sensitivity. Oncol Rep. 2017; 38(1):129-140. DOI: 10.3892/or.2017.5674. View

Christie E, Bowtell D . Acquired chemotherapy resistance in ovarian cancer. Ann Oncol. 2017; 28(suppl_8):viii13-viii15. DOI: 10.1093/annonc/mdx446. View

Xia A, Li H, Li R, Lu L, Wu X . Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression. Oncol Rep. 2018; 40(4):2353-2362. DOI: 10.3892/or.2018.6583. View

Muderrisoglu A, Babaoglu E, Korkmaz E, Ongun M, Karabulut E, Iskit A . Effects of Genetic Polymorphisms of Drug Transporter ABCB1 (MDR1) and Cytochrome P450 Enzymes CYP2A6, CYP2B6 on Nicotine Addiction and Smoking Cessation. Front Genet. 2020; 11:571997. PMC: 7734344. DOI: 10.3389/fgene.2020.571997. View

10.

Meisel H . Biochemical properties of peptides encrypted in bovine milk proteins. Curr Med Chem. 2005; 12(16):1905-19. DOI: 10.2174/0929867054546618. View

11.

Wang W, Gu F, Wei C, Tang Y, Zheng X, Ren M . PGPIPN, a therapeutic hexapeptide, suppressed human ovarian cancer growth by targeting BCL2. PLoS One. 2013; 8(4):e60701. PMC: 3622516. DOI: 10.1371/journal.pone.0060701. View

12.

Choi Y, Meghani K, Brault M, Leclerc L, He Y, Day T . Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. Cell Rep. 2016; 14(3):429-439. PMC: 4731274. DOI: 10.1016/j.celrep.2015.12.046. View

13.

Qu Z, Louis Sam Titus A, Xuan Z, DMello S . Neuroprotection by Heat Shock Factor-1 (HSF1) and Trimerization-Deficient Mutant Identifies Novel Alterations in Gene Expression. Sci Rep. 2018; 8(1):17255. PMC: 6250741. DOI: 10.1038/s41598-018-35610-1. View

14.

Barnett R . Ovarian cancer. Lancet. 2016; 387(10025):1265. DOI: 10.1016/s0140-6736(16)30024-1. View

15.

Koshiyama M, Matsumura N, Konishi I . Subtypes of Ovarian Cancer and Ovarian Cancer Screening. Diagnostics (Basel). 2017; 7(1). PMC: 5373021. DOI: 10.3390/diagnostics7010012. View

16.

Zhao M, Wei C, Yang X, Zhou J, Wang J, Gu F . The milk-derived hexapeptide PGPIPN inhibits the invasion and migration of human ovarian cancer cells by regulating the expression of MTA1 and NM23H1 genes. Int J Oncol. 2016; 48(4):1721-9. DOI: 10.3892/ijo.2016.3390. View

17.

Xing F, Zhang L, Tang Z, Li X, Gong H, Wang B . [Effect of thoraco-laparoscopic esophagectomy on postoperative immune function of patients with esophageal carcinoma]. Nan Fang Yi Ke Da Xue Xue Bao. 2021; 41(1):146-150. PMC: 7867483. DOI: 10.12122/j.issn.1673-4254.2021.01.22. View

18.

Vaidyanathan A, Sawers L, Gannon A, Chakravarty P, Scott A, Bray S . ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. Br J Cancer. 2016; 115(4):431-41. PMC: 4985349. DOI: 10.1038/bjc.2016.203. View

19.

Zhang Z, Dou X, Yang H, Jia L, Qin K, Gao X . Association of expression of p53, livin, ERCC1, BRCA1 and PARP1 in epithelial ovarian cancer tissue with drug resistance and prognosis. Pathol Res Pract. 2020; 216(2):152794. DOI: 10.1016/j.prp.2019.152794. View

20.

Fiedorowicz E, Jarmolowska B, Iwan M, Kostyra E, Obuchowicz R, Obuchowicz M . The influence of μ-opioid receptor agonist and antagonist peptides on peripheral blood mononuclear cells (PBMCs). Peptides. 2010; 32(4):707-12. DOI: 10.1016/j.peptides.2010.12.003. View